Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.47 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998037 | 0.84 | IDH1 (0.48) | ALDH1A1LMNASMN1; SMN2ALOX5IDH1 | |
| SCHEMBL4289115 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2ALOX5NPSR1 | |
| SCHEMBL23663326 | 0.78 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2ALOX5NPSR1 | |
| SCHEMBL4286746 | 0.77 | NPSR1 (0.42) | ALDH1A1LMNASMN1; SMN2ALOX5NPSR1 | |
| SCHEMBL27767698 | 0.71 | NPSR1 (0.44) | ALDH1A1LMNASMN1; SMN2ALOX5NPSR1 | |
| SCHEMBL2579095 | 0.70 | ALOX5 (0.54) | ALDH1A1LMNASMN1; SMN2ALOX5IDH1 | |
| SCHEMBL15325999 | 0.70 | SLC5A2 (0.51) | ALDH1A1LMNASMN1; SMN2LTA4H | |
| SCHEMBL2579101 | 0.70 | AMY1A (0.54) | ALOX5IDH1ALOX15IGF1RLTA4H | |
| SCHEMBL4288652 | 0.70 | MEN1 (0.45) | ALDH1A1LMNAALOX15CYP2D6 | |
| SCHEMBL4283897 | 0.70 | HPGD (0.54) | ALDH1A1LMNANPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101472937-A | Benzylphenylglucopyranoside Derivatives | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 896/4885LMNA 3975/4885SMN1; SMN2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.